Home » Biota to Merge With Nabi and List on Nasdaq for Better Capital Access
Biota to Merge With Nabi and List on Nasdaq for Better Capital Access
Australian drug development company Biota, which makes the flu drug Relenza, plans to merge with U.S.-based Nabi Biopharmaceuticals to form a combined company to be listed on Nasdaq.
The Australian
The Australian
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May